MedTrace Logo

Strategies for Assessment of Fluid Overload in Acute Decompensated Heart Failure

NCT04901039 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2024-03-07

No results posted yet for this study

Summary

Heart failure (HF) is the endstage of all heart disease, characterized by inability of either the left or right heart or both to maintain sufficient output of blood for the demands of the body at normal filling pressures. Patients with HF are often admitted to hospital with decompensation and treated with diuretics. Residual congestion at discharge is associated with increased risk of early rehospitalization and adverse outcomes. However, determination of residual decompensation is complicated and a large number of patients admitted with decompensated heart failure are likely discharged before optimal decongestion has been achieved. Lung ultrasound (LUS) is a promising method to determine residual decompensation with the evaluation of B-lines. In this study our primary aim is to evaluate if LUS together with echocardiographic evaluation of filling pressure according to the European Society of Cardiology (ESC) algorithm performs better than clinical assessment to determine fluid status and risk of early rehospitalization in patients hospitalized for AHF.

Conditions

Interventions

OTHER

Lung ultrasound

Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging

OTHER

Echocardiography

Comprehensive echocardiography with evaluation of filling pressures

OTHER

Peripheral venous pressure

Assessment of peripheral venous pressure

OTHER

Magnetic resonance imaging

Cardiac magnetic resonance imaging

OTHER

Pulmonary scintigraphy

Assessment of pulmonary perfusion with scintigraphy

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Caroline Heijl, MD, PhD · Cardiology Department, Lund University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04901039 on ClinicalTrials.gov